Comment from Association for Accessible Medicines

Summary: The Association for Accessible Medicines (AAM) supports the FDA's efforts to explore drug repurposing for unmet medical needs, provided that the framework preserves existing intellectual property and regulatory standards. They recommend that the FDA consider the operational impacts on generic drug labeling, utilize real-world evidence, and maintain transparency and stakeholder engagement throughout the process.